Skip to main content
. 2001 Sep 25;98(20):11142–11147. doi: 10.1073/pnas.211424998

Figure 3.

Figure 3

Potency of the antagonists [Glu11]Ast and [Glu11,16]Ast in the plus-maze behavior of C57BL/6J mice. The antagonists and agonists were injected i.c.v. 30 and 15 min, respectively, before exposure to the elevated plus-maze for 5 min. (A) Sixty picomoles (230 ng) of [Glu11]Ast, 20 pmol (90 ng) of oCRF; (B) 120 pmol (430 ng) of [Glu11,16]Ast, 20 pmol of oCRF; (C) 120 pmol (450 ng) of α-hel-CRF9–41, 35 pmol (170 ng) of oCRF; (D) 120 pmol of [Glu11,16]Ast, 35 pmol of oCRF. Statistically significant differences were determined by t tests: *, P < 0.05 vs. aCSF; **, P < 0.01 vs. aCSF; ***, P < 0.001 vs. aCSF; a, P < 0.05 vs. oCRF; b, P < 0.01 vs. oCRF; c, P < 0.001 vs. oCRF.